Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<ul>
<li>Hoya reported its 4QFY03/20 results on Friday (8th May) which saw YoY decline in both revenue and operating profit as a result of the Covid-19 outbreak and a JPY4.7bn fine related to a settlement with the US Department of Justice. The reported revenue was 2.7% below consensus estimates while OP beat consensus estimates by 20.1%.</li>
</ul>
<table class="table table-striped">
<colgroup> <col> <col span="2"> <col> <col> <col> </colgroup>
<tbody>
<tr>
<td style="width: 126.8px;">JPY (bn)</td>
<td style="text-align: right; width: 85.2px;">4QFY03/19</td>
<td style="text-align: right; width: 85.2px;">4QFY03/20</td>
<td style="text-align: right; width: 75.2px;">% YoY</td>
<td style="text-align: right; width: 100.8px;">Consensus</td>
<td style="text-align: right; width: 128px;">Actual Vs Consensus</td>
</tr>
<tr>
<td style="width: 126.8px;">Revenue</td>
<td style="text-align: right; width: 85.2px;">141.5</td>
<td style="text-align: right; width: 85.2px;">135.1</td>
<td style="text-align: right; width: 75.2px;">-4.5%</td>
<td style="text-align: right; width: 100.8px;">138.9</td>
<td style="text-align: right; width: 128px;">-2.7%</td>
</tr>
<tr>
<td style="width: 126.8px;">Operating Profit</td>
<td style="text-align: right; width: 85.2px;">35.1</td>
<td style="text-align: right; width: 85.2px;">32.6</td>
<td style="text-align: right; width: 75.2px;">-7.1%</td>
<td style="text-align: right; width: 100.8px;">27.1</td>
<td style="text-align: right; width: 128px;">20.1%</td>
</tr>
<tr>
<td style="width: 126.8px;">OPM</td>
<td style="text-align: right; width: 85.2px;">24.8%</td>
<td style="text-align: right; width: 85.2px;">24.1%</td>
<td style="text-align: right; width: 75.2px;"> </td>
<td style="text-align: right; width: 100.8px;">19.5%</td>
<td style="text-align: right; width: 128px;"> </td>
</tr>
<tr>
<td style="width: 126.8px;">Pre-Tax Profit</td>
<td style="text-align: right; width: 85.2px;">31.4</td>
<td style="text-align: right; width: 85.2px;">27.7</td>
<td style="text-align: right; width: 75.2px;">-11.8%</td>
<td style="text-align: right; width: 100.8px;">26.4</td>
<td style="text-align: right; width: 128px;">4.9%</td>
</tr>
<tr>
<td style="width: 126.8px;">Pre-tax Margin</td>
<td style="text-align: right; width: 85.2px;">22.2%</td>
<td style="text-align: right; width: 85.2px;">20.5%</td>
<td style="text-align: right; width: 75.2px;"> </td>
<td style="text-align: right; width: 100.8px;">19.0%</td>
<td style="text-align: right; width: 128px;"> </td>
</tr>
<tr>
<td style="width: 126.8px;">Net Income</td>
<td style="text-align: right; width: 85.2px;">29.2</td>
<td style="text-align: right; width: 85.2px;">19.7</td>
<td style="text-align: right; width: 75.2px;">-32.5%</td>
<td style="text-align: right; width: 100.8px;">24.9</td>
<td style="text-align: right; width: 128px;">-20.9%</td>
</tr>
<tr>
<td style="width: 126.8px;">Net Margin</td>
<td style="text-align: right; width: 85.2px;">20.6%</td>
<td style="text-align: right; width: 85.2px;">14.6%</td>
<td style="width: 75.2px;"> </td>
<td style="text-align: right; width: 100.8px;">17.9%</td>
<td style="width: 128px;"> </td>
</tr>
</tbody>
</table>
<div class="content-caption">Source: Company Disclosures, Cap IQ</div>
<ul class="">
<li>On a segmental basis, the Lifecare segment’s revenue decreased as a result the Japanese consumption tax hike and the Covid-19 outbreak which led to store closures.</li>
<li>However, the IT segment continued to perform strongly and reported a 5% YoY increase in revenue driven by EUV mask blanks and 3.5” HDD substrates which helped offset the decline in 2.5” substrates and imaging products.</li>
</ul>


Hoya reported its 4QFY03/20 results on Friday (8th May) which saw YoY decline in both revenue and operating profit as a result of the Covid-19 outbreak and a JPY4.7bn fine related to a settlement with the US Department of Justice. The reported revenue was 2.7% below consensus estimates while OP beat consensus estimates by 20.1%.


      


JPY (bn)
4QFY03/19
4QFY03/20
% YoY
Consensus
Actual Vs Consensus


Revenue
141.5
135.1
-4.5%
138.9
-2.7%


Operating Profit
35.1
32.6
-7.1%
27.1
20.1%


OPM
24.8%
24.1%
 
19.5%
 


Pre-Tax Profit
31.4
27.7
-11.8%
26.4
4.9%


Pre-tax Margin
22.2%
20.5%
 
19.0%
 


Net Income
29.2
19.7
-32.5%
24.9
-20.9%


Net Margin
20.6%
14.6%
 
17.9%
 



Source: Company Disclosures, Cap IQ

On a segmental basis, the Lifecare segment’s revenue decreased as a result the Japanese consumption tax hike and the Covid-19 outbreak which led to store closures.
However, the IT segment continued to perform strongly and reported a 5% YoY increase in revenue driven by EUV mask blanks and 3.5” HDD substrates which helped offset the decline in 2.5” substrates and imaging products.


Hoya 4Q Results: Temporary Drop in Lifecare Revenues; EUV Blanks/HDD Deliver Excellent Results

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

ja research

ja research is an independent research platform focused exclusively on Japanese equities. Leveraging data and graphic analysis provided by Japan Analytics, we provide insights on small and medium-sized companies that have been ignored by the sell-side as well as challenging conventional wisdom on larger companies. We also offer analyst and corporate access, the latter with translation if required. 

Quantitative Analysis

<div class="content-caption">
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/121/814/original/naakt-jpg.png?1583659197" class="editor-image img-responsive" data-smartkarma-image-id="121814"></figure>Source  • <a href="https://hollandbesthotels.wordpress.com/" target="_blank" rel="noopener">https://hollandbesthotels.wordpress.com/</a>
</div><blockquote><a href="http://www.berkshirehathaway.com/2001ar/2001letter.html" target="_blank" aria-describedby="external-disclaimer" rel="noopener">“You only find out who is swimming naked when the tide goes out. “</a>- Warren Buffett</blockquote>WHO'S SWIMMING NAKED? - This is the first part of three Insights that will in the spirit of Buffett's famous quip, attempt to highlight those Japanese companies that at the greatest risk from the 2020 Covid-19 recession. We will focus on three factors - the Audit Score, the Altman Z-Score and Cumulative Cash Flows - that individually, and in combination, can highlight those companies most at risk.<hr><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/121/877/original/2020-03-09_07-18-54.png?1583705968" class="editor-image img-responsive" data-smartkarma-image-id="121877"></figure><div class="content-caption">Source • Japan Analytics</div>PART 1: AUDIT SCORE - This factor is 'hiding in plain sight'. Since 2003, the Auditors' Opinion has been available in a format that allows 'parsing' into a database format and the creation of an 'Audit Score'. Although often a coincident rather than a leading indicator, by cumulating the score from year to year, patterns can emerge that highlight unfolding risks as in the case of <a href="https://www.smartkarma.com/entities/leopalace21-corp" target="_blank" data-smartkarma-citation="entities:8244:1" rel="noopener">Leopalace21 Corp (8848 JP)</a> above.


Source  • https://hollandbesthotels.wordpress.com/
“You only find out who is swimming naked when the tide goes out. “- Warren BuffettWHO'S SWIMMING NAKED? - This is the first part of three Insights that will in the spirit of Buffett's famous quip, attempt to highlight those Japanese companies that at the greatest risk from the 2020 Covid-19 recession. We will focus on three factors - the Audit Score, the Altman Z-Score and Cumulative Cash Flows - that individually, and in combination, can highlight those companies most at risk.Source • Japan AnalyticsPART 1: AUDIT SCORE - This factor is 'hiding in plain sight'. Since 2003, the Auditors' Opinion has been available in a format that allows 'parsing' into a database format and the creation of an 'Audit Score'. Although often a coincident rather than a leading indicator, by cumulating the score from year to year, patterns can emerge that highlight unfolding risks as in the case of Leopalace21 Corp (8848 JP) above.   

🇯🇵 JAPAN • Who's Swimming Naked? > Part 1: Audit Score

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

After the worst week in US equity markets in a long time, with sharply rising equity volatility causing risk parity funds and their ilk to shed what looked like $100bn+ of delta, and S&amp;P500 ETFs to see $20bn+ redeemed (amid fears of the possible uncontrollable spread of COVID-19 coronavirus), there were strong rumours of imminent coordinated central bank action over the weekend to prove that governments around the world were willing to act quickly to counter fears of economic weakness.We didn't get that. We got suggestions from Italy they would produce a stimulus package. German lawmakers tussled over whether or not stimulus was appropriate. EU officials high and low suggested that for the moment EU-level spending was inappropriate, some US politicians got upset that coronavirus test kits for the uninsured cost $3000+ (they don't), other politicians suggested $3000 was fine because the free market determined the price, and a president suggested the entire coronavirus thing was simultaneously a terrible blow to China and "fake news" - a hoax by the "deep state" and Democrats to try to injure his presidency (whatever else will be remembered by history in the decades to come, there will be memes).One central bank on Monday, however, did its thing.The BOJ governor issued an inter-meeting statement for the first time in many years. It was a simple statement, which said very little. <figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/121/375/original/Screenshot%202020-03-04%20at%2010.08.27%20PM.png?1583330921" class="editor-image img-responsive" data-smartkarma-image-id="121375"></figure>Given an ongoing program of ETF buying and JGB YCC/QQE, it was not clear what this meant, however, by day-end, it WAS clear.<div class="content-highlight">The BOJ had symbolically stepped in to buy ¥100.2bn of ETFs - its largest one-day purchase program in many years. </div>That leaves us with a "What Next" question. Discussion ensues below.

After the worst week in US equity markets in a long time, with sharply rising equity volatility causing risk parity funds and their ilk to shed what looked like $100bn+ of delta, and S&amp;P500 ETFs to see $20bn+ redeemed (amid fears of the possible uncontrollable spread of COVID-19 coronavirus), there were strong rumours of imminent coordinated central bank action over the weekend to prove that governments around the world were willing to act quickly to counter fears of economic weakness.We didn't get that. We got suggestions from Italy they would produce a stimulus package. German lawmakers tussled over whether or not stimulus was appropriate. EU officials high and low suggested that for the moment EU-level spending was inappropriate, some US politicians got upset that coronavirus test kits for the uninsured cost $3000+ (they don't), other politicians suggested $3000 was fine because the free market determined the price, and a president suggested the entire coronavirus thing was simultaneously a terrible blow to China and "fake news" - a hoax by the "deep state" and Democrats to try to injure his presidency (whatever else will be remembered by history in the decades to come, there will be memes).One central bank on Monday, however, did its thing.The BOJ governor issued an inter-meeting statement for the first time in many years. It was a simple statement, which said very little. Given an ongoing program of ETF buying and JGB YCC/QQE, it was not clear what this meant, however, by day-end, it WAS clear.The BOJ had symbolically stepped in to buy ¥100.2bn of ETFs - its largest one-day purchase program in many years. That leaves us with a "What Next" question. Discussion ensues below.

Equity L/S Analyst | Forensic Accounting | India, Yellowstone Equity

Ankit Agrawal, CFA

Equity L/S Analyst | Forensic Accounting | India

Forensic Accounting

In this Smartkarma Original, we bring to you a forensic analysis tool that scores companies across Developed Asia on their accounting risk. We use 25+ accounting parameters in our framework to come up with an accounting risk score. Our tool is based in Excel and is linked dynamically to Capital IQ for fetching latest data.
Insight Flow
<ol>
<li>Forensic Analysis Framework</li>
<li>Excel Model
<ol>
<li>How to Download and Use the Tool</li>
<li>Steps to Run the Model</li>
</ol>
</li>
<li>Target Universe</li>
<li>Companies with Highest Accounting Risk </li>
<li>Summary Statistics from our Analysis</li>
<li>Key Model Limitations and Risks</li>
<li>Appendix
<ol>
<li>List of Companies in our Target Universe with Accounting Risk Score &gt;= 8</li>
<li>Glossary</li>
<li>Snapshot of Capital IQ Screener Used for Filtering Universe</li>
<li>Switch Formula Calculation Option in Excel</li>
<li>Refresh Worksheet Option in Capital IQ Plugin</li>
</ol>
</li>
</ol>
<div class="content-highlight">
What's Original?
Over time with experience and taking cues from past financial shenanigans, we have developed a proprietary quantitative framework for identifying accounting irregularities. This framework comprises of 25+ accounting parameters and takes into account 10 years of historical data to assess the quality of accounting.
</div>

In this Smartkarma Original, we bring to you a forensic analysis tool that scores companies across Developed Asia on their accounting risk. We use 25+ accounting parameters in our framework to come up with an accounting risk score. Our tool is based in Excel and is linked dynamically to Capital IQ for fetching latest data.
Insight Flow

Forensic Analysis Framework
Excel Model

How to Download and Use the Tool
Steps to Run the Model


Target Universe
Companies with Highest Accounting Risk 
Summary Statistics from our Analysis
Key Model Limitations and Risks
Appendix

List of Companies in our Target Universe with Accounting Risk Score &gt;= 8
Glossary
Snapshot of Capital IQ Screener Used for Filtering Universe
Switch Formula Calculation Option in Excel
Refresh Worksheet Option in Capital IQ Plugin




What's Original?
Over time with experience and taking cues from past financial shenanigans, we have developed a proprietary quantitative framework for identifying accounting irregularities. This framework comprises of 25+ accounting parameters and takes into account 10 years of historical data to assess the quality of accounting.


A Forensic Analysis Tool for Detecting Accounting Red Flags: Focus on Developed Asia

Thematic (Sector/Industry)

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/118/403/original/2020-02-18_08-44-22.png?1581983074" class="editor-image img-responsive" data-smartkarma-image-id="118403"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/118/404/original/2020-02-18_08-42-56.png?1581983098" class="editor-image img-responsive" data-smartkarma-image-id="118404"></figure><div class="content-caption">Source • Japan Analytics</div>THREE-YEAR LOW - With <a href="https://www.smartkarma.com/entities/bridgestone-corp" target="_blank" data-smartkarma-citation="entities:8914:1" rel="noopener">Bridgestone (5108 JP)</a>'s results and revision now added, our final tally for this season is a 196 basis point decline in our Results Sore - the lowest since March 2017.  In contrast, the Forecast/Revision Score reached a three-month high as the 470 companies with December year-ends put an optimistic gloss on their medium-term outlook. As we have noted in our recent daily roundups, a normal precondition for a cycle low is for the Forecast/Revision Score to rise above the Results Score. Forecast/Revision Score peaks and troughs usually occur one to two quarters ahead of those for the Results Score.  Covid-19's impact will likely see the 2016 'playbook' repeated next quarter with a lower Results Score and a 'sideways' Forecast/Results Score. The Results Score cycle low point will be reached with the mostly-interim results to be released in six months. <figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/118/405/original/2020-02-18_09-29-28.png?1581985792" class="editor-image img-responsive" data-smartkarma-image-id="118405"></figure><div class="content-caption">Source • Japan Analytics</div>LEADING INDICATOR - By including several momentum factors into our Scoring (see below), we can provide a better indication of future business conditions. Indeed there is a 0.83 correlation between the Cabinet Office's Business Condition Leading Indicator and the Forecast/Revision Score. Reported earnings, as well as company forecasts, are lagging indicators and, as shown in Part 1 of this Insight. Both data series peaked one year after our Scores and the market peaked in early 2018. SCORING METHODOLOGY - For those new to these Insights, we briefly recap our scoring methodology below:-<ul>
<li>Results Scores are calculated using the most recent eight quarters of company data for Revenues, Operating Income and Operating Margin and, for each, measure the rate, degree and consistency of change. The Results Score has a maximum of +30 and a minimum of -30 for each period. Our data series commences from the time a particular company issues quarterly results. The sample size becomes significant from March 2005.</li>
<li>The Forecast/Revision Score is based on both Annual and Interim period company forecasts and compares changes from previous forecasts as well as against the trailing twelve-month (TTM) or previous first-half results, with annual forecasts being double-weighted. This Score also has a maximum of +30 and a minimum of -30 for each period.  For this series, our data samples start from August 2008.</li>
<li>The combined Results &amp; Revision Score (RRS) is the average of the Results Score and the Forecasts/Revision Score.</li>
<li>
All company Scores are then cap-weight-aggregated into Sector, Peer Group and Market Composite Scores for which the seventeen-year monthly and two-year daily track records are shown above. Only currently listed-companies are covered in the aggregate Scores, and the Total Market Capitalisation excludes delisted entities. REITs are not included.
<hr>
• SECTOR SCORES •
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/118/410/original/2020-02-18_09-55-29.png?1581987489" class="editor-image img-responsive" data-smartkarma-image-id="118410"></figure><div class="content-caption">Source • Japan Analytics</div>
In the DETAIL Section below, we provide a detailed breakdown of our RRS Scoring for Sectors, Peer Groups and individual companies, highlighting this quarter's 'winners' and 'losers'. The chart above shows a  seventeen-year 'timeline' of the cap-weight-aggregated Sector RRS Scores and the ebbs and flows around the business cycles. The Metals Sector is the most volatile on the downside and has yet to 'bottom' this cycle. Technology Hardware appears to have already rebounded; however, Covid-19 suggests this Sector may relapse. On the upside, the Information Technology Sector has replaced the Internet and Telecoms Sectors as the contra-cyclical 'champion'. 
</li>
</ul>

Source • Japan AnalyticsTHREE-YEAR LOW - With Bridgestone (5108 JP)'s results and revision now added, our final tally for this season is a 196 basis point decline in our Results Sore - the lowest since March 2017.  In contrast, the Forecast/Revision Score reached a three-month high as the 470 companies with December year-ends put an optimistic gloss on their medium-term outlook. As we have noted in our recent daily roundups, a normal precondition for a cycle low is for the Forecast/Revision Score to rise above the Results Score. Forecast/Revision Score peaks and troughs usually occur one to two quarters ahead of those for the Results Score.  Covid-19's impact will likely see the 2016 'playbook' repeated next quarter with a lower Results Score and a 'sideways' Forecast/Results Score. The Results Score cycle low point will be reached with the mostly-interim results to be released in six months. Source • Japan AnalyticsLEADING INDICATOR - By including several momentum factors into our Scoring (see below), we can provide a better indication of future business conditions. Indeed there is a 0.83 correlation between the Cabinet Office's Business Condition Leading Indicator and the Forecast/Revision Score. Reported earnings, as well as company forecasts, are lagging indicators and, as shown in Part 1 of this Insight. Both data series peaked one year after our Scores and the market peaked in early 2018. SCORING METHODOLOGY - For those new to these Insights, we briefly recap our scoring methodology below:-
Results Scores are calculated using the most recent eight quarters of company data for Revenues, Operating Income and Operating Margin and, for each, measure the rate, degree and consistency of change. The Results Score has a maximum of +30 and a minimum of -30 for each period. Our data series commences from the time a particular company issues quarterly results. The sample size becomes significant from March 2005.
The Forecast/Revision Score is based on both Annual and Interim period company forecasts and compares changes from previous forecasts as well as against the trailing twelve-month (TTM) or previous first-half results, with annual forecasts being double-weighted. This Score also has a maximum of +30 and a minimum of -30 for each period.  For this series, our data samples start from August 2008.
The combined Results &amp; Revision Score (RRS) is the average of the Results Score and the Forecasts/Revision Score.

All company Scores are then cap-weight-aggregated into Sector, Peer Group and Market Composite Scores for which the seventeen-year monthly and two-year daily track records are shown above. Only currently listed-companies are covered in the aggregate Scores, and the Total Market Capitalisation excludes delisted entities. REITs are not included.

• SECTOR SCORES •
Source • Japan Analytics
In the DETAIL Section below, we provide a detailed breakdown of our RRS Scoring for Sectors, Peer Groups and individual companies, highlighting this quarter's 'winners' and 'losers'. The chart above shows a  seventeen-year 'timeline' of the cap-weight-aggregated Sector RRS Scores and the ebbs and flows around the business cycles. The Metals Sector is the most volatile on the downside and has yet to 'bottom' this cycle. Technology Hardware appears to have already rebounded; however, Covid-19 suggests this Sector may relapse. On the upside, the Information Technology Sector has replaced the Internet and Telecoms Sectors as the contra-cyclical 'champion'. 



🇯🇵 JAPAN • IT’S A WRAP! Part 2: 2020-Q1 Results & Revision Scores

Japan

Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. The Company's products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems, artificial organs, and electronic thermometers. Terumo markets the products through its subsidiaries and sales offices in the US, Europe, and Asia.

SYSMEX CORPORATION manufactures reagents and equipment for clinical tests including hematologic (blood) and immune tests. The Company also develops, manufactures, and trades particle analyzers such as blood coagulation analyzer and related software. Manufacturing and sales outside Japan include the United States, EMEA, China and Asia Pacific regions.

ASAHI INTECC CO., LTD. manufactures medical tools as well as both medical and industrial-use stainless wire rope.  The Company's main products include catheters, guidewires, and miniature coils for endoscopic devices.

JEOL Ltd. manufactures electron optics instruments and analytical instruments including electron microscope, X-ray diffractometer and spectrometer and thermographs.  The Company also makes semiconductor manufacturing equipment, medical equipment and industrial equipment.

NIHON KOHDEN CORPORATION develops, manufactures, and sells medical equipment, transformers, and power switches and devices.  The Company's products include testing equipment for cerebral nerve such as electroencephalographs, circulatory systems, diagnostic equipment, catheters, biogenic monitoring systems such as electrocardiographs used into patient monitoring systems.

MANI, INC. manufactures medical goods and equipment.  The Company's products include threads and needles for surgeries, surgical knives for eye surgeries, and dental instruments and equipment.

FUKUDA DENSHI CO., LTD. manufactures and wholesales electronic equipment for medical use.  The Company's products include electrocardiograph, phonocardiogram, ultrasonic diagnosis systems, physical condition monitoring systems, pacemakers, and respirators.

NIPRO CORPORATION manufactures medical products.  The Company's products include artificial dialysis and blood transfusion equipment, hypodermic syringes, and glass products for medical use.

NAKANISHI INC. manufactures gyration equipment for dental and industry use. The Company's products include precision spindles and hand-held grinders.

Paramount Bed Holdings Company Ltd. operates as a holding company. The Company, through its subsidiaries, designs and manufactures hospital, medical, electric, motorized, and orthopedic beds.

STERIS Public Limited Company operates as a provider of infection prevention and other procedural products and services. The Company offers sterilizers and washers, surgical tables, lights and equipment management systems, and endoscopy accessories. STERIS serves healthcare, pharmaceutical, and medical device industries.

West Pharmaceutical Services, Inc. applies value-added services to the process of bringing new drug therapies and healthcare products to global markets. The Company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.

West Pharmaceutical Services Inc (WST US)

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets heated humidification products and systems for use in respiratory care and the treatment of sleep apnea.  The Company also offers patient warming and neonatal care products, including warming products and infant resuscitators.

Teleflex Incorporated is a global provider of medical technology products. The Company primarily develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes.

Hologic, Inc. is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.

Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company's products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and research laboratories.

BioMerieux designs, develops, manufactures, and markets systems in the field of in vitro diagnostics for medical and industrial applications. The Company is specialized in the diagnosis of infectious diseases and pathologies. BioMerieux is also active in the analysis of food, pharmaceuticals and environmental samples to determine their microbiological quality.

Sartorius Stedim Biotech develops and manufactures laboratory technologies and equipment for the pharma and food industries, as well as for public research institutes and laboratories.

Sartorius AG manufactures and markets precision electronic equipment and components.  The Company produces precision scales for laboratory and industrial uses and electrochemistry.  Sartorius manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation, and purification.  The Company markets its products worldwide.

OLYMPUS CORPORATION manufactures optoelectronic products.  The Company's products include cameras, video sets, endoscopes for medicine and industrial use, microscopes, analytical equipment, office communication systems, laseroptical scanners, and ionic printers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Olympus Corp (7733 JP)

Hoya 4Q Results: Temporary Drop in Lifecare Revenues; EUV Blanks/HDD Deliver Excellent Results

Hoya reported its 4QFY03/20 results on Friday (8th May) which saw YoY decline in both revenue and operating profit as a result of the Covid-19...

Shifara Samsudeen, ACMA, CGMA

🇯🇵 JAPAN • Who's Swimming Naked? > Part 1: Audit Score

“You only find out who is swimming naked when the tide goes out. “- Warren BuffettWHO'S SWIMMING NAKED? - This is the first part of three Insights...

Campbell Gunn

Coronavirus QE, the BOJ, and ETF Buying

After the worst week in US equity markets in a long time, with sharply rising equity volatility causing risk parity funds and their ilk to shed...

Travis Lundy

A Forensic Analysis Tool for Detecting Accounting Red Flags: Focus on Developed Asia

In this Smartkarma Original, we bring to you a forensic analysis tool that scores companies across Developed Asia on their accounting risk. We use...

Ankit Agrawal, CFA

🇯🇵 JAPAN • IT’S A WRAP! Part 2: 2020-Q1 Results & Revision Scores

THREE-YEAR LOW - With Bridgestone (5108 JP)'s results and revision now added, our final tally for this season is a 196 basis point decline in our...

Campbell Gunn

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)